Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. (Q34136829)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. (English)

1 reference

Europe PubMed Central

31 July 2017

Ehlers-Danlos syndrome

0 references

circulatory system

1 reference

based on heuristic

inferred from title

12

object named as

Anne De Paepe

0 references

Xavier Jeunemaitre

14

object named as

Xavier Jeunemaitre

1 reference

Europe PubMed Central

31 July 2017

Julie De Backer

object named as

Julie De Backer

3

0 references

Pierre Boutouyrie

object named as

Pierre Boutouyrie

16

0 references

author name string

Kim-Thanh Ong

1

1 reference

Europe PubMed Central

31 July 2017

Jérôme Perdu

2

1 reference

Europe PubMed Central

31 July 2017

Erwan Bozec

4

1 reference

Europe PubMed Central

31 July 2017

Patrick Collignon

5

1 reference

Europe PubMed Central

31 July 2017

Joseph Emmerich

6

1 reference

Europe PubMed Central

31 July 2017

Anne-Laure Fauret

7

1 reference

Europe PubMed Central

31 July 2017

Jean-Noël Fiessinger

8

1 reference

Europe PubMed Central

31 July 2017

Dominique P Germain

9

1 reference

Europe PubMed Central

31 July 2017

Gabriella Georgesco

10

1 reference

Europe PubMed Central

31 July 2017

Jean-Sebastien Hulot

11

1 reference

Europe PubMed Central

31 July 2017

Henri Plauchu

13

1 reference

Europe PubMed Central

31 July 2017

Stéphane Laurent

15

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

7 September 2010

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

376

1 reference

Europe PubMed Central

31 July 2017

9751

1 reference

Europe PubMed Central

31 July 2017

1476-1484

1 reference

Europe PubMed Central

31 July 2017

Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased carotid wall stress in vascular Ehlers-Danlos syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory complications of Ehlers-Danlos syndrome type IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Marfan syndrome: abnormal aortic elastic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aneurysm syndromes caused by mutations in the TGF-beta receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating transforming growth factor-beta in Marfan syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between cytokine concentrations and wound healing in chronic venous ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factor betas are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a beta2 adrenergic agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of celiprolol, a new beta 1-alpha 2 blocker, on the cardiovascular response to exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemodynamic effects of celiprolol in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960960-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)60960-9

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34136829&oldid=1965368767"